World’s First Integrated Imaging Service for Long Covid approved by UK’s MHRA. Read more.
Chief Financial Officer (CFO)
David Gill joined Perspectum in February 2021 and looks forward to bringing his operating, finance, investor relations and transaction experience to bear in accessing capital markets to fund growth and create shareholder value.
In his last operating position Mr. Gill joined EndoChoice (NYSE: GI) in August 2014as CFO, executed its IPO in 2015, and then later assumed the added roles of President and Chief Operating Officer. EndoChoice was a 500-employee public medical device company with operations in US, Germany and Israel. As President, COO and CFO, Gill was responsible for all manufacturing, R&D, supply chain, pathology lab services, finance and IT. Boston Scientific acquired Endochoice in late 2016. Prior to EndoChoice Mr. Gill served in a variety of senior leadership roles (president, COO and CFO) for several healthcare related companies, including INC Research (now known as Syneos), TransEnterix, NxStage Medical, CTI Molecular Imaging, Novoste Corporation and Dornier Medical. Currently, Mr. Gill serves on the boards of three public companies including Y-mAbs Therapeutics (YMAB) an immuno-oncology company focused on pediatric brain cancer, Evolus (EOLS), an aesthetics company, and Stonebridge Biopharma (SBBP) a rare disease company. Mr. Gill has led the IPO’s of four companies and has raised more than $1.3 Billion in equity and debt during his career. Mr. Gill has also been involved in several corporate sale transactions as either a corporate officer or board member. Mr. Gill started his career as a Certified Public Accountant with Price Waterhouse. He graduated with cum laude honors from Wake Forest University with a B.S. in Accounting and earned an MBA (with distinction) from Emory University.